Combination of phototherapy with immune checkpoint blockade: Theory and practice in cancer
Y Zhao, X Liu, X Liu, J Yu, X Bai, X Wu, X Guo… - Frontiers in …, 2022 - frontiersin.org
Immune checkpoint blockade (ICB) therapy has evolved as a revolutionized therapeutic
modality to eradicate tumor cells by releasing the brake of the antitumor immune response …
modality to eradicate tumor cells by releasing the brake of the antitumor immune response …
Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension—Mechanisms and Mitigation
LE Butel-Simoes, TJ Haw, T Williams, S Sritharan… - …, 2023 - Am Heart Assoc
Cardiovascular disease and cancer are 2 of the leading causes of death worldwide.
Although improvements in outcomes have been noted for both disease entities, the success …
Although improvements in outcomes have been noted for both disease entities, the success …
Real-world experience in treatment of patients with non-small-cell lung cancer with Braf or Cmet exon 14 skipping mutations
U Janzic, W Shalata, K Szymczak… - International Journal of …, 2023 - mdpi.com
BRAF and cMET exon 14 skipping are rare mutations of NSCLC. The treatment sequence in
these cases for the first and second line is not clear. An international registry was created for …
these cases for the first and second line is not clear. An international registry was created for …
Identification of dihydrolipoamide dehydrogenase as potential target of vemurafenib-resistant melanoma cells
C Tabolacci, D Giordano, S Rossi, M Cordella… - Molecules, 2022 - mdpi.com
Background: Despite recent improvements in therapy, the five-year survival rate for patients
with advanced melanoma is poor, mainly due to the development of drug resistance. The …
with advanced melanoma is poor, mainly due to the development of drug resistance. The …
A PD-L1xCD3 bispecific nanobody as a novel T-cell engager in treating PD-L1 overexpression melanoma
B Li, S Wang, B Shan, B Li, F Li - Molecular Immunology, 2023 - Elsevier
The development of Immune checkpoint blockade (ICB) therapy and BRAF-and MEK-
targeted therapies has reshaped the survival outcomes of the patients with advanced …
targeted therapies has reshaped the survival outcomes of the patients with advanced …
Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence
P Rogala, AM Czarnecka, B Cybulska-Stopa… - Journal of clinical …, 2022 - mdpi.com
Background: Currently, limited data on targeted therapy and immunotherapy sequencing in
patients with BRAF-mutant melanoma is available. Targeted therapy and immunotherapy …
patients with BRAF-mutant melanoma is available. Targeted therapy and immunotherapy …
Targeted therapeutic strategies for melanoma
S Zhang, R Xie, A Zhong, J Chen - Chinese Medical Journal, 2023 - mednexus.org
Melanoma accounts for a small proportion of skin cancers diagnosed each year, but it has a
high degree of malignancy and rapid progression, resulting in a short survival period for …
high degree of malignancy and rapid progression, resulting in a short survival period for …
SILAC-based quantification reveals modulation of the immunopeptidome in BRAF and MEK inhibitor sensitive and resistant tumor cells
M Bernhardt, A Rech, M Berthold, M Lappe, JN Herbel… - bioRxiv, 2024 - biorxiv.org
The immunopeptidome is constantly monitored by T cells to detect foreign or aberrant HLA
peptides. It is highly dynamic and reflects the current cellular state, enabling the immune …
peptides. It is highly dynamic and reflects the current cellular state, enabling the immune …
Efficacy and safety of Nivolumab in patients with advanced esophageal, gastroesophageal, and gastric cancers: a meta-analysis of randomized controlled trials
Background Immune checkpoint inhibitors (ICI) have revolutionized care in oncology with
improved overall survival in several cancer populations. Nivolumab has recently been …
improved overall survival in several cancer populations. Nivolumab has recently been …
Construction of immunotherapy-related prognostic gene signature and small molecule drug prediction for cutaneous melanoma
J Xing, Z Jia, Y Li, Y Han - Frontiers in Oncology, 2022 - frontiersin.org
Background Cutaneous melanoma (CM), a kind of skin cancer with a high rate of advanced
mortality, exhibits a wide variety of driver and transmitter gene alterations in the …
mortality, exhibits a wide variety of driver and transmitter gene alterations in the …